Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C66H112N20O21 |
| Molecular Weight | 1521.7169 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O
InChI
InChIKey=PHEWVCZHSBTZFX-DBCSJUPNSA-N
InChI=1S/C66H112N20O21/c1-30(2)21-43(81-54(96)36(12)75-58(100)42(17-19-49(91)92)80-65(107)52(34(9)10)86-63(105)45(23-32(5)6)84-61(103)46(24-38-25-70-29-74-38)83-56(98)39(67)28-87)60(102)76-37(13)55(97)82-44(22-31(3)4)62(104)85-51(33(7)8)64(106)77-35(11)53(95)72-26-47(88)78-41(16-18-48(89)90)59(101)79-40(15-14-20-71-66(68)69)57(99)73-27-50(93)94/h25,29-37,39-46,51-52,87H,14-24,26-28,67H2,1-13H3,(H,70,74)(H,72,95)(H,73,99)(H,75,100)(H,76,102)(H,77,106)(H,78,88)(H,79,101)(H,80,107)(H,81,96)(H,82,97)(H,83,98)(H,84,103)(H,85,104)(H,86,105)(H,89,90)(H,91,92)(H,93,94)(H4,68,69,71)/t35-,36-,37-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1
| Molecular Formula | C66H112N20O21 |
| Molecular Weight | 1521.7169 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 8 |
| Optical Activity | UNSPECIFIED |
NBI-6024 belongs to a proprietary altered peptide ligand (APL) technology developed by Neurocrine Biosciences for the treatment of autoimmune diseases. It is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production. NBI-6024 corresponds to the 9-23 amino acid region of the insulin B chain (B(9-23)), an epitope recognized by inflammatory interferon-gamma-producing T helper (Th)1 lymphocytes in type 1 diabetic patients. NBI-6024 is designed specifically to generate an immune response that could result in preservation of beta-islet cell function in patients with Type I diabetes or juvenile-onset diabetes. Because there is progressive beta-islet destruction in Type I diabetes, an early intervention strategy with a product like NBI-6024 could delay or prevent insulin dependence.
Approval Year
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:41:07 GMT 2023
by
admin
on
Sat Dec 16 08:41:07 GMT 2023
|
| Record UNII |
OMF3CT7D4L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
239480-61-6
Created by
admin on Sat Dec 16 08:41:07 GMT 2023 , Edited by admin on Sat Dec 16 08:41:07 GMT 2023
|
PRIMARY | |||
|
DB05819
Created by
admin on Sat Dec 16 08:41:07 GMT 2023 , Edited by admin on Sat Dec 16 08:41:07 GMT 2023
|
PRIMARY | |||
|
OMF3CT7D4L
Created by
admin on Sat Dec 16 08:41:07 GMT 2023 , Edited by admin on Sat Dec 16 08:41:07 GMT 2023
|
PRIMARY | |||
|
9812645
Created by
admin on Sat Dec 16 08:41:07 GMT 2023 , Edited by admin on Sat Dec 16 08:41:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
